Literature DB >> 34169819

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.

Alberto Mateo-Urdiales1,2, Stefania Spila Alegiani3, Massimo Fabiani1, Patrizio Pezzotti1, Antonietta Filia1, Marco Massari3, Flavia Riccardo1, Marco Tallon4, Valeria Proietti5, Martina Del Manso1,2, Maria Puopolo6, Matteo Spuri1, Cristina Morciano7, Fortunato Paolo D'Ancona1, Roberto Da Cas3, Serena Battilomo5, Antonino Bella1, Francesca Menniti-Ippolito3.   

Abstract

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0-14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21-0.24) 43-49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09-0.15) and 93% (IRR: 0.07; 95% CI: 0.04-0.11) reductions 36-42 days post-first dose. Our results support ongoing vaccination campaigns.

Entities:  

Keywords:  COVID-19; Italy; pandemic; vaccination

Year:  2021        PMID： 34169819     DOI： 10.2807/1560-7917.ES.2021.26.25.2100507

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  9 in total

1.  Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.

Authors:  Chiara Sacco; Martina Del Manso; Alberto Mateo-Urdiales; Maria Cristina Rota; Daniele Petrone; Flavia Riccardo; Antonino Bella; Andrea Siddu; Serena Battilomo; Valeria Proietti; Patrizia Popoli; Francesca Menniti Ippolito; Anna Teresa Palamara; Silvio Brusaferro; Giovanni Rezza; Patrizio Pezzotti; Massimo Fabiani
Journal:  Lancet       Date:  2022-07-01       Impact factor: 202.731

2.  Group Vaccination Five Days before a COVID-19 Outbreak in a Long-Term Care Facility.

Authors:  Mathias W Pletz; Sabine Trommer; Steffi Kolanos; Norman Rose; Veit Kinne; Riccardo Spott; Michael Baier; Isabel Lange
Journal:  Vaccines (Basel)       Date:  2021-12-08

3.  Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021.

Authors:  Chiara Sacco; Alberto Mateo-Urdiales; Daniele Petrone; Matteo Spuri; Massimo Fabiani; Maria Fenicia Vescio; Marco Bressi; Flavia Riccardo; Martina Del Manso; Antonino Bella; Patrizio Pezzotti
Journal:  Euro Surveill       Date:  2021-11

4.  Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.

Authors:  Massimo Fabiani; Maria Puopolo; Cristina Morciano; Matteo Spuri; Stefania Spila Alegiani; Antonietta Filia; Fortunato D'Ancona; Martina Del Manso; Flavia Riccardo; Marco Tallon; Valeria Proietti; Chiara Sacco; Marco Massari; Roberto Da Cas; Alberto Mateo-Urdiales; Andrea Siddu; Serena Battilomo; Antonino Bella; Anna Teresa Palamara; Patrizia Popoli; Silvio Brusaferro; Giovanni Rezza; Francesca Menniti Ippolito; Patrizio Pezzotti
Journal:  BMJ       Date:  2022-02-10

5.  Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.

Authors:  Maxime Taquet; Quentin Dercon; Paul J Harrison
Journal:  Brain Behav Immun       Date:  2022-04-18       Impact factor: 19.227

6.  Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.

Authors:  Massimo Fabiani; Maria Puopolo; Antonietta Filia; Chiara Sacco; Alberto Mateo-Urdiales; Stefania Spila Alegiani; Martina Del Manso; Fortunato D'Ancona; Fenicia Vescio; Marco Bressi; Daniele Petrone; Matteo Spuri; Maria Cristina Rota; Marco Massari; Roberto Da Cas; Cristina Morciano; Paola Stefanelli; Antonino Bella; Marco Tallon; Valeria Proietti; Andrea Siddu; Serena Battilomo; Anna Teresa Palamara; Patrizia Popoli; Silvio Brusaferro; Giovanni Rezza; Flavia Riccardo; Francesca Menniti Ippolito; Patrizio Pezzotti
Journal:  Expert Rev Vaccines       Date:  2022-04-15       Impact factor: 5.683

7.  Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan.

Authors:  Hafez Al-Momani; Khawla Aldajah; Ebtisam Alda'ajah; Yousef ALjafar; Zainab Abushawer
Journal:  Front Public Health       Date:  2022-09-21

8.  When to end a lock down? How fast must vaccination campaigns proceed in order to keep health costs in check?

Authors:  Claudius Gros; Thomas Czypionka; Daniel Gros
Journal:  R Soc Open Sci       Date:  2022-01-26       Impact factor: 2.963

9.  The Effectiveness of a Diverse COVID-19 Vaccine Portfolio and Its Impact on the Persistence of Positivity and Length of Hospital Stays: The Veneto Region's Experience.

Authors:  Silvia Cocchio; Federico Zabeo; Giacomo Facchin; Nicolò Piva; Patrizia Furlan; Michele Nicoletti; Mario Saia; Michele Tonon; Michele Mongillo; Francesca Russo; Vincenzo Baldo
Journal:  Vaccines (Basel)       Date:  2022-01-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.